SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (972)11/21/1997 2:49:00 PM
From: D.Right  Respond to of 2173
 
Dear David:

Thanks for you post. I do have another question though. In case AMLN needs to go to a subgroup to show a higher degree of efficiency in the on-going trials, how many patients you need in each group to be statistically significant? For example, 80 out of 120 in the type I trials or more? And in the type II European trial, 70 out of 100?

I appreciate your help.

D.Right


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News